Current stock page

Catalysts

KYMR Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

KYMRKymera Therapeutics, Inc.

Healthcare / Biotechnology

Absolute Strength

Above Peers

BullishEdge 7/10
$127.57+$0.40 (+0.31%)

Latest quote

  • Momentum
    87
  • Value
    43
  • Quality
    57
  • Risk resilience
    60
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 65/100

Momentum 87/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 29.44%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 87/100AIQ Edge 7/10 Above Peers
Beat rate
38%
3 of 8 reported periods
Average surprise
-5.2%
Across covered historical reports
Latest result
-4.8%
Oct 29, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 29, 2026—-$1.26-$1.32-4.8%$3.28M$1.35M
Aug 5, 2026—-$0.71-$0.62+13.0%$32.78M$65M
Apr 30, 2026—-$0.89-$0.71+20.2%$8.27M$34.37M
Feb 26, 2026—-$0.78-$0.97-23.8%$15.05M$2.87M
Nov 4, 2025—-$0.71-$0.90-26.8%$14.45M$2.76M
Aug 11, 2025—-$0.83-$0.95-14.5%$17.13M$11.48M
May 9, 2025—-$0.92-$0.82+10.9%$12.38M$22.1M
Feb 27, 2025—-$0.76-$0.88-15.8%$16.68M$7.39M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
22
Buy
2
Hold
12-month analyst target
$150.57
+18.03% versus current price
Based on 24 analyst observations. Targets are estimates, not predictions.
Low target
$132.00
+3.47% vs latest price
Average target
$150.57
+18.03% vs latest price
High target
$180.00
+41.10% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate-$1.29

Current analyst expectation for the upcoming report.

Revenue estimate$253.33K

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score87

Where event reaction would show up first.

AIQ score65/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
24
Average target
$150.57
Target upside
18.03%
Target range
$132.00 - $180.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Nov 2, 2026

Kymera Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:KYMR) 2026-11-02

2026-11-02. The following slide deck was published by Kymera Therapeutics, Inc.

gurufocus.com · Oct 5, 2026

KYMR Maintained by Citigroup -- Price Target Raised to $150

Kymera Therapeutics (KYMR) Analyst Rating Update On October 5, 2026, Citigroup analyst Geoff Meacham announced that Kymera Therapeutics (KYMR) has been maint

gurufocus.com · Sep 28, 2026

JPMorgan Flags Kymera Therapeutics (KYMR) for Positive Catalyst Ahead of Phase 2b Trial Results

On September 28, 2026, JPMorgan analyst Brian Cheng placed Kymera Therapeutics Inc (NASDAQ: KYMR) under a "Positive Catalyst Watch" while reaffirming an Overwei

gurufocus.com · Sep 24, 2026

KYMR Looks 178.8% Overvalued on GF Value™

On September 24, 2026, Goldman Sachs restarted its analysis of Kymera Therapeutics Inc (NASDAQ: KYMR), classifying it as an Early-Stage Biotech company amid a r

gurufocus.com · Sep 22, 2026

KYMR Maintained by Stifel -- Price Target Raised to $152

Kymera Therapeutics: Analyst Rating Update and Valuation Insights On October 03, 2023, Stifel maintained a 'Buy' rating on Kymera Therapeutics (KYMR) and inc

Open full news and sentiment

KYMR Catalysts FAQ

What are the next catalysts for KYMR stock?

KYMR's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move KYMR stock?

Upcoming events that could move KYMR include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could KYMR's next earnings report affect the stock?

KYMR's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive KYMR stock higher?

KYMR could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt KYMR stock?

KYMR could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.